Mild Alzheimer's Disease - Study 2
Study Name: Mild Alzheimer’s Disease - Study 2
Clinics: Barnsley, Cannock and Manchester
Therapy Area: Alzheimer’s Disease
Gender and Age: Males and Females aged 50 - 85
MAC Clinical Research is currently conducting a clinical trial for Mild Alzheimer’s Disease. The trial objective is to evaluate the effects of administration of a new treatment on Mild Alzheimer’s Disease.
During the treatment period, participants will receive the study drug 8 times: 4 times with 4-week intervals, then 3 times with 12-week intervals, and 1 time with a 26-week interval and must attend 20 clinic visits and be available to receive 4 telephone calls.
Reimbursement: We will reimburse travel expenses or provide transport.
Key Inclusion Criteria:
A diagnosis of mild Alzheimer’s Disease (AD) or probable Alzheimer’s.
Must have a project partner.
Received a stable AD medication for > 3 months (excluding memantine).
Key Exclusion Criteria:
Patients with other medical conditions that may influence cognitive impairment, including, but not limited to, vascular dementia, dementia with Lewy bodies and Parkinson’s disease.
History of haemorrhagic stroke, cancer and autoimmune disease.
History of epilepsy or unexplained seizure within the past 5 years.
History of major psychiatric disorder within the past 2 years, including thoughts of suicide.
Other eligibility criteria will apply. Please contact MAC for more information.
Any other information
Eligible patients will receive a comprehensive health screen and study participation will be in collaboration with the patient’s treating physician.